Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | NOS1 | P29475 | 9/20 | 0.72 |
| ▸ | NOS3 | P29474 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | DDAH1 | O94760 | 6/20 | 0.68 |
| ▸ | THPO | P40225 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL43261 | 1.00 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30679324 | 1.00 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30577923 | 1.00 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30631154 | 1.00 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL288993 | 1.00 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL31547986 | 0.98 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30074239 | 0.98 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL29361849 | 0.98 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL15152867 | 0.96 | NOS2 (0.92) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL1532506 | 0.96 | NOS2 (0.92) | NOS2CYP2C19CYP1A2TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729934-A1 | ANALYSIS DEVICE | Canon Kabushiki Kaisha (JP) | 2026-04-22 | — | — | EP | claimed |
| US-20260092890-A1 | ANALYTICAL DEVICE | CANON KK (JP) | 2026-04-02 | — | — | US | claimed |
| WO-2025046367-A2 | ASSEMBLY OF BAGS, USE THEREOF, AND HOLDER THEREFOR | WE-AG Invest GmbH (DE) | 2025-03-06 | — | — | WO | claimed |
| WO-2024257725-A1 | ANALYSIS DEVICE | キヤノン株式会社 | 2024-12-19 | — | — | WO | claimed |
| CN-119080883-A | Antibacterial peptide and application thereof | 合肥科生景肽生物科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| EP-4250614-B1 | APPARATUS AND METHOD FOR TRANSMITTING AND RECEIVING PACKETS IN A MOBILE COMMUNICATION SYSTEM SUPPORTING HYBRID AUTOMATIC REPEAT REQUEST | SAMSUNG ELECTRONICS CO LTD (KR) | 2024-07-10 | — | — | EP | claimed |
| US-20240100071-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2024-03-28 | — | — | US | claimed |
| EP-4210505-A2 | FOOD SUPPLEMENT OR MEDICINAL OR PHARMACEUTICAL COMPOSITION INHIBITING VIRUS INFECTION, ADVANTAGEOUSLY INFECTION OF SARS-COV-2 AND IBV CORONAVIRUSES AND FORMULATION THEREOF | Gyulai László (HU) | 2023-07-19 | — | — | EP | claimed |
| CN-115443285-A | PBP 3-binding bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2022-12-06 | — | — | CN | claimed |
| EP-4062566-A1 | APERIODIC SCHEDULING REQUEST | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2022-09-28 | — | — | EP | claimed |
| CN-114521197-A | Hetero-tandem bicyclic peptide complexes | 拜斯科技术开发有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-114502598-A | Hetero-tandem bicyclic peptide complexes | 拜斯科技术开发有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-114478708-A | Solid phase synthesis method of ganirelix fragment | 南京汉欣医药科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-114341190-A | EphA2 specific bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-111603505-A | Vasodilator formulations and methods of use | ATP研究有限公司 | 2020-09-01 | — | — | CN | claimed |
| CN-105873581-A | vasodilator formulations and methods of use | ATP研究有限公司 | 2016-08-17 | — | — | CN | claimed |
| US-20140228435-A1 | COMPOSITION AND METHOD OF SYNTHESIZING A BIOMOLECULE AND ITS THERAPEUTICS APPLICATIONS | BAKHTIARI MEHDI (IR) | 2014-08-14 | — | — | US | claimed |
| US-20100121105-A1 | Composition and Method of synthesizing a biomolecule and its therapeutics applications | BAKHTIARI MEHDI | 2010-05-13 | — | — | US | claimed |
| US-4327031-A | (2-OXO-3-BORNYLIDENE METHYL) BENZENESULFONIC ACID | L'OREAL (FR) | 1982-04-27 | — | — | US | claimed |
| US-4304730-A | SUNSCREEN AGENTS | L'OREAL (FR) | 1981-12-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228435-A1 | COMPOSITION AND METHOD OF SYNTHESIZING A BIOMOLECULE AND ITS THERAPEUTICS APPLICATIONS | PRKCZ, PRKCH, PRKCD | NOS2 174/4885CYP2C19 4128/4885CYP1A2 4230/4885 |
| US-20260092890-A1 | ANALYTICAL DEVICE | TMEM63A, TMEM14C, ORAI1 | NOS2 4860/4885CYP2C19 3935/4885CYP1A2 4714/4885 |
| US-20100121105-A1 | Composition and Method of synthesizing a biomolecule and its therapeutics applications | GHRHR, GHSR, IGF1R | NOS2 878/4885CYP2C19 4669/4885CYP1A2 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.